Analysts See $-0.16 EPS for Avid Bioservices, Inc. (CDMO) as of July, 13

June 27, 2018 - By Alex Paulin

Earnings report for Avid Bioservices, Inc. (NASDAQ:CDMO) is expected on July, 13., according to RTT. The earnings per share diference is $0.00 or 0.00 % from last years number. Previous year: $-0.16; Analysts forcast: $-0.16. Last quarter $-0.23 earnings per share was reported. Analysts sees -30.43 % EPS growth this quarter. CDMO reached $3.78 during the last trading session after $0.02 change.Avid Bioservices, Inc. is downtrending after having declined 14.38% since June 27, 2017. CDMO has 533,108 volume or 0.02% up from normal. The stock underperformed the S&P 500 by 26.95%.

Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture.The firm is valued at $209.99 million. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.Currently it has negative earnings. The firm produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support.

For more Avid Bioservices, Inc. (NASDAQ:CDMO) news announced briefly go to:,,, or The titles are as follows: “Consolidated Research: 2018 Summary Expectations for Rayonier Advanced Materials, CYS Investments, Avid …” announced on June 14, 2018, “Mid-Morning Market Update: Markets Open Lower; Carnival Cuts Profit Forecast” on June 25, 2018, “Orgenesis, Inc. – Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline” with a publish date: June 03, 2018, “Midday Stock Roundup” and the last “Benzinga’s Top Upgrades, Downgrades For June 25, 2018” with publication date: June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.